The Tamesis
However, R&D efforts in automation and artificial intelligence are driving growth in manufacturing.
The outlook for cell and gene therapies (CGT) for respiratory diseases remains under pressure, with limited clinical progress and reduced funding, according to a report from GlobalData.
CGT’s venture funding has dropped significantly in recent years, from $750 million in 2021 to $330 million in 2024. Meanwhile, development in the respiratory field remains limited, with no approved treatments and only one product in Phase III trials.
Connor Daniels, a healthcare analyst at GlobalData, said a lack of understanding of disease mechanisms can lead to slow development. This includes idiopathic pulmonary fibrosis, as well as the heterogeneity of patients with chronic obstructive pulmonary disease,
Despite these limitations, R&D efforts focused on automation and artificial intelligence are improving manufacturing capabilities, an area widely seen as a bottleneck for CGT.
In October 2025, Made Scientific and Streamline Bio announced a collaboration to accelerate AI-driven robotic manufacturing following validation efforts.
“These developments will help overcome the manufacturing challenges currently faced by CGT while ensuring product quality is maintained, ultimately lowering the cost of these therapies for patients and payers,” Daniels added.
The companies said the technology is designed to adapt to different equipment and production methods.
